Literature DB >> 1533231

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

E Fischer1, M A Marano, K J Van Zee, C S Rock, A S Hawes, W A Thompson, L DeForge, J S Kenney, D G Remick, D C Bloedow.   

Abstract

The present study was undertaken to evaluate the extent to which an endogenous interleukin-1 (IL-1) response contributes to the hemodynamic and metabolic consequences of sublethal endotoxemia or lethal Gram-negative septic shock. Young, healthy baboons received either a sublethal dose of lipopolysaccharide (LPS) or an LD100 of live Escherichia coli bacteria, and one half of the animals in each group were continuously infused with IL-1 receptor antagonist (IL-1ra). Plasma IL-1 beta was not detected in this model of endotoxemia. Administration of IL-1ra had only minimal effects on the modest hemodynamic and metabolic responses to sublethal endotoxemia, and did not attenuate the plasma cytokine response. In contrast, high circulating levels of IL-1 beta (range 300-800 pg/ml) were seen during lethal E. coli septic shock. IL-1ra treatment significantly attenuated the decrease in mean arterial blood pressure (MAP) (from -72 +/- 8 to -43 +/- 6 mm Hg; P less than 0.05) and cardiac output (from -0.81 +/- 0.17 to -0.48 +/- 0.15 liter/min; P less than 0.05), and significantly improved survival from 43 to 100% at 24 h (P less than 0.05). The plasma IL-1 beta and IL-6 responses to lethal E. coli septic shock were also significantly diminished by IL-1ra treatment (P less than 0.05), whereas tumor necrosis factor-alpha (TNF alpha) concentrations were unaffected. We conclude that an exaggerated systemic IL-1 beta response is characteristic of lethal E. coli septic shock, and contributes significantly to the hemodynamic and metabolic consequences of E. coli septic shock. IL-1ra can significantly attenuate the cytokine cascade and improve survival.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533231      PMCID: PMC443028          DOI: 10.1172/JCI115748

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Two high-affinity interleukin 1 receptors represent separate gene products.

Authors:  R Chizzonite; T Truitt; P L Kilian; A S Stern; P Nunes; K P Parker; K L Kaffka; A O Chua; D K Lugg; U Gubler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

3.  Interleukin 1 receptor blockade attenuates the host inflammatory response.

Authors:  J E Gershenwald; Y M Fong; T J Fahey; S E Calvano; R Chizzonite; P L Kilian; S F Lowry; L L Moldawer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

4.  Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.

Authors:  C A Dinarello; T Ikejima; S J Warner; S F Orencole; G Lonnemann; J G Cannon; P Libby
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

5.  In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.

Authors:  J K McIntosh; D M Jablons; J J Mulé; R P Nordan; S Rudikoff; M T Lotze; S A Rosenberg
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

6.  Detection of circulating tumor necrosis factor after endotoxin administration.

Authors:  H R Michie; K R Manogue; D R Spriggs; A Revhaug; S O'Dwyer; C A Dinarello; A Cerami; S M Wolff; D W Wilmore
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

7.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

8.  Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.

Authors:  Y Fong; K J Tracey; L L Moldawer; D G Hesse; K B Manogue; J S Kenney; A T Lee; G C Kuo; A C Allison; S F Lowry
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

9.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.

Authors:  A Waage; T Espevik
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Authors:  C A Dinarello; J G Cannon; S M Wolff; H A Bernheim; B Beutler; A Cerami; I S Figari; M A Palladino; J V O'Connor
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  56 in total

Review 1.  Differential Paradigms in Animal Models of Sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

2.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

3.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

Review 4.  The evolution of an inflammatory response.

Authors:  Stephen F Lowry
Journal:  Surg Infect (Larchmt)       Date:  2009-10       Impact factor: 2.150

5.  The soluble tumor necrosis factor receptor I is an early predictor of local infective complications after colorectal surgery.

Authors:  Robert Slotwiński; Waldemar L Olszewski; Andrzej Chaber; Maciej Slodkowski; Marzanna Zaleska; Ireneusz W Krasnodebski
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

6.  High dynamic range characterization of the trauma patient plasma proteome.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; Wenzhong Xiao; Lyle L Moldawer; Amit Kaushal; Matthew E Monroe; Susan M Varnum; Ronald J Moore; Samuel O Purvine; Ronald V Maier; Ronald W Davis; Ronald G Tompkins; David G Camp; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2006-05-09       Impact factor: 5.911

Review 7.  Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts.

Authors:  G Maschmeyer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Glomerular expression of interleukin-1 receptor antagonist and interleukin-1 beta genes in antibody-mediated glomerulonephritis.

Authors:  F W Tam; J Smith; S J Cashman; Y Wang; E M Thompson; A J Rees
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock.

Authors:  M A Rogy; H S Oldenburg; S E Calvano; W J Montegut; S A Stackpole; K J Van Zee; M N Marra; R W Scott; J J Seilhammer; L L Moldawer
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

10.  Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.

Authors:  A S Hawes; E Fischer; M A Marano; K J Van Zee; C S Rock; S F Lowry; S E Calvano; L L Moldawer
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.